Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879068 | 1.00 | CTBP2 (0.36) | CTBP2KDM4EALDH1A1MAPTCA12 | |
| SCHEMBL6077166 | 0.89 | KDM4E (0.42) | KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL6077162 | 0.89 | KDM4E (0.42) | KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL6872170 | 0.88 | NPC1 (0.40) | CA12CA1CA2CA9TRPM8 | |
| SCHEMBL6872168 | 0.88 | NPC1 (0.40) | CA12CA1CA2CA9TRPM8 | |
| SCHEMBL3681999 | 0.87 | TDP1 (0.39) | CTBP2ALDH1A1MAPTCA12CA1 | |
| SCHEMBL6877326 | 0.87 | ACHE (0.45) | CTBP2ALDH1A1TRPM8TAS2R14 | |
| SCHEMBL3682001 | 0.87 | TDP1 (0.39) | CTBP2ALDH1A1MAPTCA12CA1 | |
| SCHEMBL6876913 | 0.87 | BCL2A1 (0.43) | CTBP2ALDH1A1 | |
| SCHEMBL6877322 | 0.87 | ACHE (0.45) | CTBP2ALDH1A1TRPM8TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176495-A1 | HIV Integrase inhibitors | MAPT, RIF1, HPRT1 | CTBP2 2429/4885KDM4E 1398/4885ALDH1A1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.